Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | Underperform → Neutral | BofA Securities | |
| 6/17/2024 | $4.00 → $6.00 | Neutral → Overweight | Piper Sandler |
| 3/27/2023 | $6.00 | Equal Weight | Wells Fargo |
| 1/24/2023 | $115.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 1/6/2023 | $20.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/6/2023 | $71.00 → $12.00 | Overweight → Neutral | Piper Sandler |
| 1/6/2023 | Outperform → Market Perform | Cowen | |
| 1/6/2023 | $107.00 → $5.30 | Buy → Hold | Stifel |
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA
BofA Securities upgraded Fate Therapeutics from Underperform to Neutral
Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously
Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)
144 - FATE THERAPEUTICS INC (0001434316) (Subject)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza
- Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million - Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein coupled receptor biology - Radionetics expands board of directors with the appointment of Eric Shiozaki, Ph.D., Partner at DCVC Bio Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new invest
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company's common stock at an exercise price per share of $1.79, which was the closing price per share of the Company's common stock as reported by NASDAQ on January 2, 2025, the options grant date, and (ii) restricted stoc
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinica
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on December 2, 2024 the Company granted restricted stock units (RSUs) representing 18,600 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering